The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Lower-risk MDS: improving outcomes with luspatercept, imetelstat & new agents
In this video, Valeria Santini, MD, University of Florence, Florence, Italy, gives an overview of recent advances in the treatment of lower-risk myelodysplastic syndromes (LR-MDS), with a focus on therapies for anemia. She highlights findings from the COMMANDS trial (NCT03682536) of luspatercept, which has been shown to improve patient survival and transfusion independence. Prof. Santini also discusses data on imetelstat, which has shown durable responses and potential disease-modifying activity in patients with high transfusion burden. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
